<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01382017</url>
  </required_header>
  <id_info>
    <org_study_id>LCM-TMS-2010</org_study_id>
    <nct_id>NCT01382017</nct_id>
  </id_info>
  <brief_title>Effects of Lacosamide on Human Motor Cortex Excitability: a Transcranial Magnetic Stimulation Study</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Kiel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kiel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed to explore dose-depended effects of lacosamide (LCM) on motor
      cortex excitability with TMS in a randomized, double-blind, placebo-controlled crossover
      trial in young healthy human subjects, and to compare the pattern of excitability changes
      induced by LCM with those of carbamazepine (CBZ). LCM selectively enhances slow inactivation
      of voltage-gated sodium channel, and, in contrast to CBZ, does not affect steady-state fast
      inactivation (Errington et al., 2006). The enhancement of slow inactivation of sodium
      channels by LCM is a novel manner to modulate sodium channels and leads to normalization of
      activation thresholds and a reduced pathophysiological hyper-responsiveness, thereby
      effectively controlling neuronal hyperexcitability without affecting physiological activity
      (Beyreuther et al., 2007). Therefore, it is thought that LCM, compared to CBZ, will be better
      tolerated in clinical settings while being as or even more effective in controlling seizure
      activity. On the basis of the results from nonhuman studies, it is hypothesized that the TMS
      profile of LCM will be distinguishable from that of CBZ. CBZ, like other 'classical' sodium
      channel blockers such as phenytoin, predominantly demonstrated elevated TMS motor thresholds
      indicating reduced neuronal membrane excitability, without developing significant changes of
      synaptic intracortical inhibition and facilitation (Ziemann et al., 1996; Chen et al., 1997;
      Lee et al., 2005). Because of its novel mode of action it can only be speculated which TMS
      parameters LCM might affect. For example, more than exclusively affecting neuronal membrane
      excitability, LCM could possibly also affect inhibitory mechanisms such as short- and
      long-latency intracortical inhibition (Valls-Sole et al., 1992; Kujirai et al., 1993). This
      would in line with other well-tolerated modern antiepileptic drugs (Ziemann et al., 1996;
      Reis et al., 2002; Lang et al., 2006).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>TMS measures of cortical excitability</measure>
    <time_frame>within 24h after intake of study medication</time_frame>
    <description>Transcranial magnetic stimulation (TMS) measurements included resting motor thresholds (RMT) and active motor thresholds (AMT), the intensity to evoke MEP of âˆ¼1mV peak-to-peak amplitude (SI1mV), short-interval intracortical inhibition/intracortical facilitation (SICI/ICF), long-interval intracortical inhibition (LICI), short-interval intracortical facilitation (SICF), recruitment curves, MEP under tonic activation (aMEP), and cortical silent period (CSP), and MEP changes in response to short trains of repetitive TMS.</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Healthy Male Volunteers</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo arm</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lasosamide 200</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lacosamide 200 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lacosamide 400</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Lacosamide 400 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Carbamazepine 600</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Carbamazepine 600 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <description>Lacosamide 200 or 400 mg</description>
    <arm_group_label>Lasosamide 200</arm_group_label>
    <arm_group_label>Lacosamide 400</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carbamazepine</intervention_name>
    <description>Carbamazepine 600 mg</description>
    <arm_group_label>Carbamazepine 600</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  healthy

          -  male

          -  right-handed

          -  aged 18-45 years

        Exclusion Criteria:

          -  cardiac pacemaker

          -  metal implants in the head

          -  intake of any medication

          -  previous neurologic, psychiatric, or chronic internal diseases

          -  pregnancy or breastfeeding; drug, nicotine, or alcohol abuse

          -  known or expected intolerance to soy beans, peanuts, LCM or CBZ; abnormal ECG with
             prolonged PQ-interval

          -  participation in another clinical trial within the previous 8 weeks
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Lang, PD Dr. med.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Christian-Albrechts University Kiel, Germany</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Departmenr of Neurology, UKSH Campus Kiel</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.uksh.de/neurologie-kiel</url>
    <description>Department of Neurology, University of Kiel, Germany</description>
  </link>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 23, 2011</study_first_submitted>
  <study_first_submitted_qc>June 24, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <last_update_submitted>August 28, 2012</last_update_submitted>
  <last_update_submitted_qc>August 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Kiel</investigator_affiliation>
    <investigator_full_name>Nicolas Lang</investigator_full_name>
    <investigator_title>PD Dr. med.</investigator_title>
  </responsible_party>
  <keyword>lacosamide</keyword>
  <keyword>carbamazepine</keyword>
  <keyword>placebo</keyword>
  <keyword>transcranial magnetic stimulation</keyword>
  <keyword>TMS</keyword>
  <keyword>motor cortex</keyword>
  <keyword>sodium channel</keyword>
  <keyword>inhibition</keyword>
  <keyword>threshold</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
    <mesh_term>Carbamazepine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

